Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
02:08 EDT 16 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
THE WOODLANDS, Texas, Aug. 16, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX293...
Other Sources for this Article
More From BioPortfolio on "Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
